Literature DB >> 21208254

Presynaptic facilitatory adenosine A2A receptors mediate fade induced by neuromuscular relaxants that exhibit anticholinesterase activity.

Elaine Cs Bornia1, Paulo Correia-de-Sá, Wilson Alves-Do-Prado.   

Abstract

1. Pancuronium, cisatracurium and vecuronium are antinicotinic agents that, in contrast with d-tubocurarine and hexamethonium, exhibit anticholinesterase activity. Pancuronium-, cisatracurium- and vecuronium-induced fade results from blockade of facilitatory nicotinic receptors on motor nerves, but fade produced by such agents also depends on the presynaptic activation of inhibitory muscarinic M2 receptors by acetylcholine released from motor nerve terminals and activation of inhibitory adenosine A1 receptors by adenosine released from motor nerves and muscles. The participation of presynaptic facilitatory A2A receptors in fade caused by pancuronium, cisatracurium and vecuronium has not yet been investigated. In the present study, we determined the effects of ZM241385, an antagonist of presynaptic facilitatory A2A receptors, on fade produced by these neuromuscular relaxants in the rat phrenic nerve-diaphragm (PND) preparation. 2. The muscles were stimulated indirectly at 75±3Hz to induce a sustained tetanizing muscular contraction. The lowest concentration at which each antinicotinic agent produced fade without modifying initial tetanic tension (presynaptic action) was determined. 3. d-Tubocurarine-induced fade occurred only at 55 nmol/L, a concentration that also reduced maximal tetanic tension (post-synaptic action). At 10 nmol/L, ZM 241385 alone did not produce fade, but it did attenuate pancuronium (0.32 μmol/L)-, cisatracurium (0.32 μmol/L)- and vecuronium (0.36 μmol/L)-induced fade. 4. The fade induced by the 'pure' antinicotinic agents d-tubocurarine (55 nmol/L) and hexamethonium (413 μmol/L) was not altered by 10 nmol/L ZM 241385, indicating that presynaptic adenosine A2A receptors play a significant role in the fade produced by antinicotinic agents when such agents have anticholinesterase activity.
© 2011 The Authors. Clinical and Experimental Pharmacology and Physiology © 2011 Blackwell Publishing Asia Pty Ltd.

Entities:  

Keywords:  adenosine receptors; cisatracurium; muscarinic receptors; pancuronium; pirenzepine

Mesh:

Substances:

Year:  2011        PMID: 21208254     DOI: 10.1111/j.1440-1681.2011.05476.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  5 in total

1.  Effects of presynaptic muscarinic cholinoreceptor blockade on neuromuscular transmission as assessed by the train-of-four and the tetanic fade response to rocuronium.

Authors:  Yong Beom Kim; Sangseok Lee; Kyeong Chun Lee; Ha Jung Kim; Young Jin Ro; Hong-Seuk Yang
Journal:  Clin Exp Pharmacol Physiol       Date:  2017-07       Impact factor: 2.557

Review 2.  Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents.

Authors:  Yong Beom Kim; Tae-Yun Sung; Hong Seuk Yang
Journal:  Korean J Anesthesiol       Date:  2017-09-28

3.  Effects of neuromuscular presynaptic muscarinic M1 receptor blockade on rocuronium-induced neuromuscular blockade in immobilized tibialis anterior muscles.

Authors:  Yong Beom Kim; Hong-Seuk Yang; Ha Jung Kim; Hey-Ran Choi; Junyong In; Soon-Young Yoon; Young Jin Ro
Journal:  Clin Exp Pharmacol Physiol       Date:  2018-08-30       Impact factor: 2.557

4.  Effects of adenosine receptor agonist on the rocuroniuminduced neuromuscular block and sugammadex-induced recovery.

Authors:  Yong Beom Kim; Sangseok Lee; Hey Ran Choi; Junyong In; Young Jin Chang; Ha Jung Kim; Young Jin Ro; Hong-Seuk Yang
Journal:  Korean J Anesthesiol       Date:  2018-04-25

5.  Effects of sevoflurane and adenosine receptor antagonist on the sugammadex-induced recovery from rocuronium-induced neuromuscular blockade in rodent phrenic nerve-hemidiaphragm tissue specimens.

Authors:  Yong Beom Kim; Jae-Moon Choi; Chungon Park; Hey-Ran Choi; Junyong In; Hong-Seuk Yang
Journal:  Pharmacol Res Perspect       Date:  2021-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.